Table 2.
CES-D-10 and Mental Health Component score comparison in Aspirin and Placebo groups: a) all participants (primary comparison)
| n | Aspirin Mean (SD) | Placebo Mean (SD) | Differential change# (95%CI) | Effect size (Cohen’s D) | |
|---|---|---|---|---|---|
| a) CES-D-10 | |||||
| Baseline | 1,879 | 10.6 (3.2) | 10.6 (3.1) | ||
| Year 1 | 1,734 | 9.0 (5.0) | 8.2 (4.8) | 0.8 (0.3, 1.3) | 0.15 |
| Year 2 | 729 | 8.3 (5.2) | 7.9 (4.8) | 0.3 (−0.3, 1.0) | 0.09 |
| Year 3 | 1,404 | 8.6 (5.2) | 8.2 (4.8) | 0.4 (−0.1, 0.9) | 0.06 |
| Year 4 | 932 | 8.8 (5.3) | 8.1 (5.0) | 0.6 (0.0, 1.2) | 0.08 |
| Year 5 | 611 | 8.8 (5.1) | 8.3 (4.7) | 0.5 (−0.2, 1.2) | 0.07 |
| Year 6 | 194 | 8.8 (4.6) | 8.0 (4.4) | 0.8 (−0.3, 1.9) | 0.20 |
| b) Mental Health Component SF-12 | |||||
| Baseline | 1,879 | 48.1 (9.5) | 47.9 (9.3) | ||
| Year 1 | 1,732 | 48.6 (10.0) | 49.3 (8.9) | −0.9 (−1.8, 0.0) | −0.03 |
| Year 2 | 1,641 | 49.6 (9.7) | 49.5 (9.2) | 0.0 (−1.0, 0.9) | −0.00 |
| Year 3 | 1,398 | 48.7 (10.2) | 50.2 (9.0) | −1.5 (−2.6, −0.5) | −0.01 |
| Year 4 | 1,002 | 49.1 (9.9) | 49.9 (9.2) | −0.6 (−1.8, 0.6) | −0.2 |
| Year 5 | 607 | 47.8 (9.7) | 49.7 (8.8) | −1.3 (−2.7, 0.0) | −0.04 |
| Year 6 | 607 | 47.8 (9.7) | 49.7 (8.8) | −0.2 (−2.4, 2.0) | −0.07 |
Note:
#
Differential change from baseline at follow-ups (aspirin vs placebo) was estimated from two-way interaction of intervention allocation and follow-up annual visit from a GEE model that includes fixed effect of group allocation and follow-up time point and their two-way interactions; reference groups: baseline measurement and placebo group.